Pharmacological CD39 blockade with POM-1, when combined with IL-2cx treatment to redirect IL-2 activity, enhanced the accumulation of pre-exhausted CD8<sup>+</sup> T cells with cytotoxic potential, thereby improving tumor control. The gene discussed is ENTPD1; the disease is neoplasm.